Your browser doesn't support javascript.
loading
The effects of height and BMI on prostate cancer incidence and mortality: a Mendelian randomization study in 20,848 cases and 20,214 controls from the PRACTICAL consortium.
Davies, Neil M; Gaunt, Tom R; Lewis, Sarah J; Holly, Jeff; Donovan, Jenny L; Hamdy, Freddie C; Kemp, John P; Eeles, Rosalind; Easton, Doug; Kote-Jarai, Zsofia; Al Olama, Ali Amin; Benlloch, Sara; Muir, Kenneth; Giles, Graham G; Wiklund, Fredrik; Gronberg, Henrik; Haiman, Christopher A; Schleutker, Johanna; Nordestgaard, Børge G; Travis, Ruth C; Neal, David; Pashayan, Nora; Khaw, Kay-Tee; Stanford, Janet L; Blot, William J; Thibodeau, Stephen; Maier, Christiane; Kibel, Adam S; Cybulski, Cezary; Cannon-Albright, Lisa; Brenner, Hermann; Park, Jong; Kaneva, Radka; Batra, Jyotsna; Teixeira, Manuel R; Pandha, Hardev; Lathrop, Mark; Smith, George Davey; Martin, Richard M.
Afiliación
  • Davies NM; School of Social and Community Medicine, University of Bristol, Bristol, UK. neil.davies@bristol.ac.uk.
  • Gaunt TR; MRC Integrative Epidemiology Unit, University of Bristol, Bristol, UK. neil.davies@bristol.ac.uk.
  • Lewis SJ; School of Social and Community Medicine, University of Bristol, Bristol, UK.
  • Holly J; MRC Integrative Epidemiology Unit, University of Bristol, Bristol, UK.
  • Donovan JL; School of Social and Community Medicine, University of Bristol, Bristol, UK.
  • Hamdy FC; MRC Integrative Epidemiology Unit, University of Bristol, Bristol, UK.
  • Kemp JP; School of Clinical Sciences, University of Bristol, Bristol, BS10 5NB, UK.
  • Eeles R; School of Social and Community Medicine, University of Bristol, Bristol, UK.
  • Easton D; Nuffield Department of Surgery, University of Oxford, Oxford, UK.
  • Kote-Jarai Z; MRC Integrative Epidemiology Unit, University of Bristol, Bristol, UK.
  • Al Olama AA; University of Queensland Diamantina Institute, Translational Research Institute, Brisbane, QLD, Australia.
  • Benlloch S; The Institute of Cancer Research, London, SM2 5NG, UK.
  • Muir K; The Royal Marsden NHS Foundation Trust, London, SW3 6JJ, UK.
  • Giles GG; Strangeways Laboratory, Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Worts Causeway, Cambridge, UK.
  • Wiklund F; The Institute of Cancer Research, London, SM2 5NG, UK.
  • Gronberg H; Strangeways Laboratory, Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Worts Causeway, Cambridge, UK.
  • Haiman CA; Strangeways Laboratory, Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Worts Causeway, Cambridge, UK.
  • Schleutker J; Institute of Population Health, University of Manchester, Manchester, UK.
  • Nordestgaard BG; Cancer Epidemiology Centre, The Cancer Council Victoria, 615 St Kilda Road, Melbourne, VIC, Australia.
  • Travis RC; Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Melbourne, VIC, Australia.
  • Neal D; Department of Medical Epidemiology and Biostatistics, Karolinska Institute, Stockholm, Sweden.
  • Pashayan N; Department of Medical Epidemiology and Biostatistics, Karolinska Institute, Stockholm, Sweden.
  • Khaw KT; Department of Preventive Medicine, Keck School of Medicine, University of Southern California/Norris Comprehensive Cancer Center, Los Angeles, CA, USA.
  • Stanford JL; Department of Medical Biochemistry and Genetics, University of Turku, Turku, Finland.
  • Blot WJ; Institute of Biomedical Technology/BioMediTech, University of Tampere and FimLab Laboratories, Tampere, Finland.
  • Thibodeau S; Department of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, Herlev Ringvej 75, 2730, Herlev, Denmark.
  • Maier C; Cancer Epidemiology Unit, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, UK.
  • Kibel AS; Surgical Oncology (Uro-Oncology: S4), University of Cambridge, Addenbrooke's Hospital, Hills Road, Box 279, Cambridge, UK.
  • Cybulski C; Li Ka Shing Centre, Cancer Research UK Cambridge Research Institute, Cambridge, UK.
  • Cannon-Albright L; Strangeways Laboratory, Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Worts Causeway, Cambridge, UK.
  • Brenner H; Department of Applied Health Research, University College London, 1-19 Torrington Place, London, WC1E 7HB, UK.
  • Park J; Cambridge Institute of Public Health, University of Cambridge, Forvie Site, Robinson Way, Cambridge, CB2 0SR, UK.
  • Kaneva R; Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
  • Batra J; Department of Epidemiology, School of Public Health, University of Washington, Seattle, WA, USA.
  • Teixeira MR; International Epidemiology Institute, 1455 Research Blvd., Suite 550, Rockville, MD, 20850, USA.
  • Pandha H; Mayo Clinic, Rochester, MN, USA.
  • Lathrop M; Institute of Human Genetics, University Hospital Ulm, Ulm, Germany.
  • Smith GD; Brigham and Women's Hospital/Dana-Farber Cancer Institute, 45 Francis Street-ASB II-3, Boston, MA, 02115, USA.
  • Martin RM; Washington University, St. Louis, Missouri.
Cancer Causes Control ; 26(11): 1603-16, 2015 Nov.
Article en En | MEDLINE | ID: mdl-26387087
ABSTRACT

BACKGROUND:

Epidemiological studies suggest a potential role for obesity and determinants of adult stature in prostate cancer risk and mortality, but the relationships described in the literature are complex. To address uncertainty over the causal nature of previous observational findings, we investigated associations of height- and adiposity-related genetic variants with prostate cancer risk and mortality.

METHODS:

We conducted a case-control study based on 20,848 prostate cancers and 20,214 controls of European ancestry from 22 studies in the PRACTICAL consortium. We constructed genetic risk scores that summed each man's number of height and BMI increasing alleles across multiple single nucleotide polymorphisms robustly associated with each phenotype from published genome-wide association studies.

RESULTS:

The genetic risk scores explained 6.31 and 1.46% of the variability in height and BMI, respectively. There was only weak evidence that genetic variants previously associated with increased BMI were associated with a lower prostate cancer risk (odds ratio per standard deviation increase in BMI genetic score 0.98; 95% CI 0.96, 1.00; p = 0.07). Genetic variants associated with increased height were not associated with prostate cancer incidence (OR 0.99; 95% CI 0.97, 1.01; p = 0.23), but were associated with an increase (OR 1.13; 95 % CI 1.08, 1.20) in prostate cancer mortality among low-grade disease (p heterogeneity, low vs. high grade <0.001). Genetic variants associated with increased BMI were associated with an increase (OR 1.08; 95 % CI 1.03, 1.14) in all-cause mortality among men with low-grade disease (p heterogeneity = 0.03).

CONCLUSIONS:

We found little evidence of a substantial effect of genetically elevated height or BMI on prostate cancer risk, suggesting that previously reported observational associations may reflect common environmental determinants of height or BMI and prostate cancer risk. Genetically elevated height and BMI were associated with increased mortality (prostate cancer-specific and all-cause, respectively) in men with low-grade disease, a potentially informative but novel finding that requires replication.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Fenotipo / Neoplasias de la Próstata / Estatura / Índice de Masa Corporal Tipo de estudio: Clinical_trials / Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Aged / Humans / Male / Middle aged Idioma: En Revista: Cancer Causes Control Asunto de la revista: EPIDEMIOLOGIA / NEOPLASIAS Año: 2015 Tipo del documento: Article País de afiliación: Reino Unido

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Fenotipo / Neoplasias de la Próstata / Estatura / Índice de Masa Corporal Tipo de estudio: Clinical_trials / Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Aged / Humans / Male / Middle aged Idioma: En Revista: Cancer Causes Control Asunto de la revista: EPIDEMIOLOGIA / NEOPLASIAS Año: 2015 Tipo del documento: Article País de afiliación: Reino Unido